These types of treatments are commonly referred to as “disease modifiers”. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression. This is a large paradigm shift from today’s symptom-oriented therapies.

BioArctic’s proprietary technology platform, dedicated personnel, collaborations with leading academic research groups and the global pharma industry have made it possible to develop innovative treatments based on antibodies (immunotherapy) for neurodegenerative disorders.

Recent Milestones: Approval for Leqembi in the USA, Japan and China. 

Upcoming Milestones: Approvals for Leqembi in the UK, EU and other geographies.

Products: Leqembi a disease modifying treatment for Alzheimer’s disease. 

Investors: The founders of BioArctic, Lars Lannfelt and Pär Gellerfors, hold 55%. Swedish pension funds. RA Capital.

Full Company address & contact details: Oskar Bosson, ir@bioarctic.com.

https://www.bioarctic.se/en/